Research programme: CTLA4-Ig fusion proteins - Perseid Therapeutics
Alternative Names: MAXY-12; MAXY-4; MAXY-740Latest Information Update: 04 Nov 2017
At a glance
- Originator Maxygen
- Developer Perseid Therapeutics
- Class Immunoglobulin fusion proteins
- Mechanism of Action CD28 antigen inhibitors; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders; Rheumatoid arthritis; Transplant rejection
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Transplant-rejection in USA (Parenteral)